Skip to main content
. 2021 Dec 17;71(9):1843–1855. doi: 10.1136/gutjnl-2021-325180

Figure 1.

Figure 1

Schematic showing the mechanism by which tumour stroma-targeted TRAIL-NO@Nanogel suppresses PDAC progression in mice. NO released from tumour stroma-targeted TRAIL-NO@Nanogel remodels the fibrotic tumour microenvironment of desmoplastic PDAC. (1) NO released from NPs modified with tumour stroma-targeting peptides identified by phage display suppresses PSC activation, reduces ECM production and increases tumour perfusion in PDAC. (2) NO reprogrammes the desmoplastic stroma and overcomes TRAIL resistance, sensitising PDAC tumours to TRAIL therapy. (3) Co-delivery of TRAIL and NO by tumour stroma-targeted TRAIL-NO@Nanogel efficiently suppresses tumour growth. ECM, extracellular matrix; NO, nitric oxide; NPs, nanoparticle; PDAC, pancreatic ductal adenocarcinoma; PSC, pancreatic stellate cells; TRAIL, tumour necrosis factor-related apoptosis-inducing ligand.